Table 2.
Age-, sex-, and cancer-specific conditions incidence of cirAE in patients treated with ICIs.
| Characteristics | N | Incidence of cirAE-related ICI therapy | ||
|---|---|---|---|---|
| Cases | Incidence Estimated (95% CI) | |||
| Age, year | ||||
| <65 | 57 | 14 | 24.6 (15.0 – 37.5) | |
| 65-75 | 39 | 14 | 35.9 (22.4 – 52.0) | |
| >75 | 16 | 8 | 50.0 (27.1 – 72.9) | |
| Sex | ||||
| Male | 67 | 22 | 32.8 (22.6 – 45.0) | |
| Female | 45 | 14 | 31.1 (19.3 – 46.1) | |
| Cancer type | ||||
| Lung | 63 | 17 | 27.0 (17.4 – 39.3) | |
| Liver | 22 | 9 | 40.9 (22.7 – 62.0) | |
| Melanoma | 11 | 4 | 36.4 (14.2 – 66.4) | |
| Other† | 16 | 6 | 37.5 (17.8 – 62.5) | |
| Pre-ICI therapy ‡ | ||||
| Traditional chemotherapy | 56 | 15 | 26.7 (16.7 – 40.0) | |
| Radiotherapy | 5 | 1 | 20.0 (26.5 – 69.6) | |
| Targeted agent | 23 | 9 | 39.1 (21.6 – 60.0) | |
| Concurrent chemoradiation therapy | 5 | 2 | 40.0 (9.8 – 80.3) | |
| Traditional chemotherapy plus radiotherapy | 6 | 1 | 16.7 (2.2 – 63.7) | |
| None | 16 | 8 | 50.0 (27.1 – 72.9) | |
| ICI therapy | ||||
| Anti-PD-1 | 63 | 21 | 33.3 (22.7 – 45.9) | |
| Anti-PD-L1 | 44 | 13 | 29.5 (17.9 – 44.7) | |
| Anti-CTLA-4 or anti-CTLA-4 plus anti-PD-1/PD-L1 | 5 | 2 | 40.0 (9.8 – 80.3) | |
| Overall | 112 | 36 | 32.1 (24.1 – 41.4) | |
†Other cancer types included head and neck, genitourinary (renal, urothelial), bladder cancer, colorectal carcinoma, cervical cancer, and gastric cancer.
‡Missing data for one patient.
CI, confidence interval; cirAEs, cutaneous immune-related adverse events; CTLA-4, cytotoxic T-lymphocyte antigen-4; ICI, immune checkpoint inhibitor; PD-1, programmed cell death-1; PD-L1, programmed cell death-1-ligand 1.